On this page
What should CTD 3.2.S.3 explain about characterization and impurities?
Explain how the evidence supports substance identity and how relevant impurities are identified, understood and addressed. Connect each important impurity to its origin, analytical evidence, occurrence and applicable control or qualification. Preserve uncertainty where identity or safety interpretation is unresolved instead of converting a list of peaks into a conclusion.
Before you begin
M4Q(R1) S.3; applicable impurity guidance depends on substance class, impurity type and development context.
What you will prepare: An evidence map separating identity conclusions, observed/potential impurities and the control or qualification supporting each.
Sections covered in this guide (3)
S.3.1: interpret the evidence, not just attach spectra
Collect signed characterization reports, material identifiers, methods and the proposed structure from S.1. For a chemical substance, explain how the synthetic route and analytical evidence support identity, stereochemistry and relevant solid-state characteristics. Identify conflicting observations and their resolution. A stack of spectra without assignments does not tell the reviewer what conclusion each result supports.
For biotech material, organize the applicable primary/higher-order structure, modifications, biological activity, purity and immunochemical evidence. Distinguish the desired product and product-related substances from impurities using a scientifically reviewed rationale. The dossier writer should preserve that interpretation, not invent it from peak names.
S.3.2: build an impurity-to-control assessment
Create a working table with impurity identifier, known or proposed origin, detection/characterization evidence, occurrence across relevant batches, qualification rationale and control location. Include potential as well as observed concerns where the product-specific assessment calls for them. Keep process-related and degradation-related origins visible; identify residual solvents, elemental or mutagenic concerns for specialist assessment when relevant rather than forcing every issue into one numerical threshold.
For every limit proposed in S.4, locate the scientific basis. Where nonclinical qualification is used, reference the actual study and material exposure context. Different impurity classes and biotech products need different guidance; this guide supplies no universal reporting, identification or qualification limits. If identity or toxicological relevance remains unresolved, state the uncertainty and assign analytical/toxicology review.
Worked review: one impurity has two names
Fictional exercise: development reports call a degradant “Peak B,” while the proposed specification calls it “Impurity 4.” The narrative treats them as different substances and claims both are qualified.
Reconcile the identifiers using characterization evidence, map the batches and methods where the species was observed, and check the qualification reference. If equivalence cannot be established, preserve both as unresolved entries instead of merging them. Update S.4's justification and the QOS after the chemistry and safety owners resolve the relationship. An alias correction must not silently expand a study's qualification scope.
Make impurity identities and evidence traceable
Use one editorial register across characterization, specification, stability and supporting safety work. Its purpose is to reconcile names and evidence, not to choose impurity limits.
| Register field | Record explicitly | Question for the reviewer |
|---|---|---|
| Identity and aliases | Assigned structure or unresolved identifier | Do different names refer to the same species? |
| Origin | Supported process or degradation relationship | Is the origin established or only proposed? |
| Occurrence | Relevant batches, methods and conditions | Is the compared evidence analytically compatible? |
| Safety/qualification basis | Actual assessment and material exposure context | Does the cited evidence cover this impurity and use? |
| Control | Location, method and proposed criterion | Is the rationale consistent with the characterization? |
An unidentified peak should stay identifiable as an unresolved analytical observation. Do not give it a plausible chemical name merely to make the register look complete. Equally, do not treat a qualified related substance as evidence for an unassessed impurity with a similar name.
Review exercise: the stability team detects a species also discussed in process development. Establish its identity using appropriate evidence before merging the entries. If they are the same, preserve the two origins or conditions where relevant; if the relationship remains uncertain, retain separate entries and assign the question.
Reconcile the final register with S.4 controls and S.7 stability. Any changed identity or qualification scope can affect both documents even if the reported peak area has not changed.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is an impurity peak label enough to establish chemical identity?
No. A chromatographic label identifies a reported observation, not necessarily a fully established structure. Describe the characterization evidence and any remaining uncertainty. Reconcile aliases through the responsible analytical and chemistry assessment rather than assuming similarly named peaks are identical.
Can one impurity threshold be used for every substance?
No. Applicable impurity assessment depends on the substance, impurity class, exposure and regulatory context. This organization guide does not supply universal numerical thresholds. Obtain the relevant scientific assessment and current applicable guidance before presenting a reporting, control or qualification conclusion.
What belongs in S.3 rather than S.4?
S.3 explains characterization and impurity evidence. S.4 presents the control specifications, procedures, validation, batch analyses and justification. Connect the impurity rationale across them without creating independently maintained identities or inconsistent claims about what a proposed control achieves.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
ICH M4Q(R1): CTD Quality ↗Step 4, September 12, 2002; Module 3, printed pages 5–18. Organization/content guidance, not a universal list of required studies. Checked September 22, 2026. Guide-specific passages: 3.2.S.3.1–3.2.S.3.2, printed pages 9–10.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 3.2.S.3. A heading identifies placement, not mandatory applicability.